Compare Amphastar Pharmaceuticals Inc (AMPH) vs Marriott International Inc (MAR) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Marriott International (MAR) trades at $376.11, up 0.98% today, with a bearish technical signal and a consensus price target of $386.42. Recent earnings show mixed results, with Q1 2026 beating expectations but Q4 2025 missing. The company maintains strong revenue growth, reaching $26.19B in 2025, and a net income margin of 9.72%. Key developments include the launch of Ask Bonvoy AI and reaching 10,000 properties globally, though hotel owners are pushing back on loyalty program terms.

Outlook is cautiously optimistic with upside to the consensus target, supported by solid fundamentals and strategic initiatives. Risks include rising debt-to-asset ratio (58.83% in 2025), competitive pressures, and potential travel demand volatility. Analyst sentiment is mixed with 44% buy ratings, but technical indicators suggest near-term bearish pressure.